

APPLICATION NO.

10/091,360

47670

## United States Patent and Trademark Office

FILING DATE

03/04/2002

08/16/2006

7590

TWO STAMFORD PLAZA

STAMFORD, CT 06901

281 TRESSER BOULEVARD

KELLEY DRYE & WARREN LLP

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

PAPER NUMBER

	www.uspto.gov	
1	ATTORNEY DOCKET NO.	CONFIRMATION NO.
•	IK-110.3(C)	1541
	EXAMINER	
	CLOW, 1	LORI A

DATE MAILED: 08/16/2006

**ART UNIT** 

1631

Please find below and/or attached an Office communication concerning this application or proceeding.

FIRST NAMED INVENTOR

Petros Tsipouras

	Application No.	Applicant(s)
Notice of Non-Compliant	10/09/360	
Amendment (37 CFR 1.121)	Examiner	Art Unit
The MAILING DATE of this communication app	ears on the cover sheet with the c	orrespondence address
The amendment document filed on $8-7-09$ requirements of 37 CFR 1.121. In order for the amendment required.	_ is considered non-compliant be ent document to be compliant, co	ecause it has failed to meet the prection of the following item(s) is
THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE A  1. Amendments to the specification:  A. Amended paragraph(s) do not include  B. New paragraph(s) should not be under  C. Other	markings.	BE NON-COMPLIANT:
<ul> <li>2. Abstract:</li> <li>A. Not presented on a separate sheet. 37</li> <li>B. Other</li> </ul>	CFR 1.72.	
3. Amendments to the drawings:  A. The drawings are not properly identifie "Annotated Sheet" as required by 37 C  B. The practice of submitting proposed drawing amended figures, without man	ÉFR 1.121(d). awing correction has been elimin	nated. Replacement drawings
C. Other		•
<ul> <li>4. Amendments to the claims:</li> <li>A. A complete listing of all of the claims is</li> <li>B. The listing of claims does not include the claim of claim has not been provided with of each claim cannot be identified. No number by using one of the following such claims of the claims of this amendment paper he claims of this amendment paper he content.</li> <li>For further explanation of the amendment format required</li> </ul>	he text of all pending claims (include the proper status identifier, and te: the status of every claim must tatus identifiers: (Original), (Currentered), (Withdrawn) and (Withdrawe not been presented in ascen	as such, the individual status of be indicated after its claim ently amended), (Canceled), awn-currently amended).  ding numerical order.
http://www.uspto.gov/web/offices/pac/dapp/opla/preogno		The diffe title out to website at
TIME PERIODS FOR FILING A REPLY TO THIS NOTIC	E:	
<ol> <li>Applicant is given no new time period if the non-cor filed after allowance. If applicant wishes to resubmit entire corrected amendment must be resubmitted</li> </ol>	the non-compliant after-final ame	endment with corrections, the
<ol> <li>Applicant is given one month, or thirty (30) days, who corrected section of the non-compliant amendment amendment is one of the following: a preliminary american request for continued examination (RCE) under 37 C period under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendrene continued examination (RCE) under 37 CFR 1.103(a) or (c), and an amendr</li></ol>	in compliance with 37 CFR 1.12 endment, a non-final amendment (FR 1.114), a supplemental amer	1, if the non-compliant to the first the following a submission for a suspension to the filed within a suspension to the suspension to the suspension to the suspensi
Extensions of time are available under 37 CFR amendment or an amendment filed in response to	1.136(a) <u>only</u> if the non-compliant a Q <i>uayle</i> action.	t amendment is a non-final
Abandonment of the application if the non-confiled in response to a Quayle action; or	mpliant amendment is a non-final	
Non-entry of the amendment if the non-compliant amendment.	571-6	372-0541
Legal Instruments Examiner (LIE)	7	Telephone No.